MA32191B1 - Inhibiteurs du recepteur de chimiokine cxcr3 - Google Patents

Inhibiteurs du recepteur de chimiokine cxcr3

Info

Publication number
MA32191B1
MA32191B1 MA33173A MA33173A MA32191B1 MA 32191 B1 MA32191 B1 MA 32191B1 MA 33173 A MA33173 A MA 33173A MA 33173 A MA33173 A MA 33173A MA 32191 B1 MA32191 B1 MA 32191B1
Authority
MA
Morocco
Prior art keywords
chemokine receptor
receptor inhibitors
cxcr3
cxcr3 chemokine
benzsulfonamide
Prior art date
Application number
MA33173A
Other languages
Arabic (ar)
English (en)
Inventor
David S Thorpe
Martin Smrcina
Dagmar D Cabel
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA32191B1 publication Critical patent/MA32191B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Cette invention concerne un composé 3-(amido ou sulfamido)-4-(4-azinyle substitué)benzamide ou benzsulfonamide défini ici. Le composé 3-(amido ou sulfamido)-(4-azinyle substitué)benzamide ou benzsulfonamide est utile comme inhibiteur du récepteur de chimiokine cxcr3, et pour la prévention ou le traitement d'une maladie médiée par le récepteur de chimiokine cxcr3 ou d'une affection associée chez un patient le nécessitant.
MA33173A 2008-02-19 2010-09-13 Inhibiteurs du recepteur de chimiokine cxcr3 MA32191B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2973808P 2008-02-19 2008-02-19
PCT/US2009/034340 WO2009105435A1 (fr) 2008-02-19 2009-02-18 Inhibiteurs du récepteur de chimiokine cxcr3

Publications (1)

Publication Number Publication Date
MA32191B1 true MA32191B1 (fr) 2011-04-01

Family

ID=40527535

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33173A MA32191B1 (fr) 2008-02-19 2010-09-13 Inhibiteurs du recepteur de chimiokine cxcr3

Country Status (25)

Country Link
US (1) US8268828B2 (fr)
EP (1) EP2262784B1 (fr)
JP (1) JP2011512412A (fr)
KR (1) KR20100123835A (fr)
CN (1) CN102007108A (fr)
AR (1) AR070430A1 (fr)
AU (1) AU2009215643A1 (fr)
BR (1) BRPI0908815A2 (fr)
CA (1) CA2715557A1 (fr)
CL (1) CL2009000368A1 (fr)
CO (1) CO6241113A2 (fr)
CR (1) CR11604A (fr)
DO (1) DOP2010000254A (fr)
EC (1) ECSP10010409A (fr)
IL (1) IL207597A0 (fr)
MA (1) MA32191B1 (fr)
MX (1) MX2010008397A (fr)
NI (1) NI201000132A (fr)
NZ (1) NZ587380A (fr)
PE (1) PE20091576A1 (fr)
RU (1) RU2010138577A (fr)
SV (1) SV2010003648A (fr)
TW (1) TW200948791A (fr)
WO (1) WO2009105435A1 (fr)
ZA (1) ZA201005314B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
JP5807971B2 (ja) 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｘｃｒ３受容体アンタゴニスト
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
KR101251788B1 (ko) 2010-12-06 2013-04-08 기아자동차주식회사 차량 연비 정보 단말표시 시스템 및 그 방법
JP6162694B2 (ja) 2011-07-18 2017-07-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ベンズアミド類
EP2601950A1 (fr) 2011-12-06 2013-06-12 Sanofi Dérivés de l'acide carboxylique de cycloalcanes en tant qu'antagonistes du recepteur CXCR3
CN104080784B (zh) * 2012-01-10 2017-07-18 默克专利有限公司 用作卵泡刺激素调节剂的苯甲酰胺衍生物
EP2809668B1 (fr) 2012-02-02 2017-04-12 Actelion Pharmaceuticals Ltd. Composés de 4-(benzoimidazol-2-yle)-thiazole et dérivés aza associés
EP2666769A1 (fr) 2012-05-23 2013-11-27 Sanofi Dérivés dýacide B-amino substitués en tant quýantagoniste de récepteur CXCR3
SG11201600504TA (en) 2013-07-22 2016-02-26 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
US10266526B2 (en) * 2014-09-10 2019-04-23 Epizyme, Inc. Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
TWI693221B (zh) 2015-01-15 2020-05-11 瑞士商愛杜西亞製藥有限公司 作為ｃｘｃｒ３受體調節劑之羥烷基六氫吡衍生物
CA3054945A1 (fr) * 2017-03-26 2018-10-04 Takeda Pharmaceutical Company Limited Carboxamides heteroaromatiques substitues par piperidinyle et piperazinyle en tant que modulateurs de gpr6
CN115974766B (zh) * 2023-01-04 2025-05-16 中国药科大学 N-苄基-3-苯基酰胺类衍生物、包含其的药物组合物及其应用
CN116410159B (zh) * 2023-06-09 2023-08-22 济南国鼎医药科技有限公司 一种恩曲替尼中间体的制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719660A (en) 1969-06-13 1973-03-06 Takeda Chemical Industries Ltd 2-furfurylthioinosine-5'-phosphate compounds
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6469002B1 (en) 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
GB0203994D0 (en) 2002-02-20 2002-04-03 Celltech R&D Ltd Chemical compounds
EP1554253A4 (fr) 2002-06-03 2006-09-20 Smithkline Beecham Corp Composes imidazolium inhibiteurs de cxcr3
US6734659B1 (en) 2002-06-13 2004-05-11 Mykrolis Corporation Electronic interface for use with dual electrode capacitance diaphragm gauges
CN101146793A (zh) * 2005-02-16 2008-03-19 先灵公司 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物
MX2007009946A (es) * 2005-02-16 2007-09-26 Schering Corp Piperazin-piperidinas sustituidas con piridilo y fenilo con actividad antagonista de cxcr3.
EP1856098B1 (fr) 2005-02-16 2012-08-01 Schering Corporation Piperazine-piperidines pyrazinyl substituees a activite antagoniste des cxcr3
US20080312215A1 (en) * 2005-06-28 2008-12-18 Pharmacopeia Drug Discovery, Inc. Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders
US7781437B2 (en) 2005-10-11 2010-08-24 Schering Corporation Substituted heterocyclic compounds with CXCR3 antagonist activity
US20090143413A1 (en) 2005-11-29 2009-06-04 Adams Alan D Thiazole Derivatives as CXCR3 Receptor Modulators
AU2007227425A1 (en) 2006-03-21 2007-09-27 Pharmacopeia, Inc. Heterocyclic substituted pyridine compounds with CXCR3 antagonist activity
US7902199B2 (en) 2006-07-14 2011-03-08 Schering Corporation Heterocyclic substituted piperazine compounds with CXCR3 antagonist activity
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3

Also Published As

Publication number Publication date
AR070430A1 (es) 2010-04-07
CA2715557A1 (fr) 2009-08-27
CR11604A (es) 2010-10-05
EP2262784B1 (fr) 2014-04-16
NI201000132A (es) 2011-03-16
CN102007108A (zh) 2011-04-06
ZA201005314B (en) 2011-03-30
NZ587380A (en) 2011-09-30
EP2262784A1 (fr) 2010-12-22
KR20100123835A (ko) 2010-11-25
RU2010138577A (ru) 2012-03-27
CL2009000368A1 (es) 2009-06-26
ECSP10010409A (es) 2010-09-30
DOP2010000254A (es) 2010-08-31
US20100305088A1 (en) 2010-12-02
WO2009105435A1 (fr) 2009-08-27
JP2011512412A (ja) 2011-04-21
BRPI0908815A2 (pt) 2019-09-24
CO6241113A2 (es) 2011-01-20
PE20091576A1 (es) 2009-11-05
MX2010008397A (es) 2010-08-23
AU2009215643A1 (en) 2009-08-27
SV2010003648A (es) 2011-01-31
IL207597A0 (en) 2010-12-30
TW200948791A (en) 2009-12-01
US8268828B2 (en) 2012-09-18

Similar Documents

Publication Publication Date Title
MX2010008397A (es) Inhibidores del receptor de quimioquinas cxcr3.
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
DE602007010781D1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
EA200870475A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
MA30694B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
MA31963B1 (fr) Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
EA200870471A1 (ru) Замещенные пирролидиноны в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1 типа
MA32627B1 (fr) Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase
MA32887B1 (fr) Aminotetrahydropyranes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
EP1608627A4 (fr) Antagonistes des recepteurs du cgrp spirohydantoine anilides bicycliques
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
NO20084403L (no) Cykloheksylpyrazol-lactamderivater som inhibitorer av II-beta-hydroksysteroid dehydrogenase I
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
SE0403006D0 (sv) New compounds
EP1993560A4 (fr) Antagonistes de recepteur cannabinoide/agonistes inverses utiles dans le traitement de l'obesite
MA30421B1 (fr) Pyrrolidinones substituees par un piperidinyle en tant qu'inhibiteurs de la 11-bêta-hydroxysteroïde deshydrogenase 1
TN2009000012A1 (en) Amino-piperidine derivatives as cetp inhibitors
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine